Utrecht, The Netherlands
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences.
We are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.
Our goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.
Last May at the BCF Career Event NTrans Technologies has been awarded the BCF Scale-up Award. What is the story behind this upcoming life science business? https://www.bcfcareer.nl/bcf-scale-up-award-winner-2019/ The story of NTrans Technologies starts in 2015 in the laboratories of the Hubrecht Institute of the Royal Netherlands Academy of Sciences (NWO).
John van der Oost (Scientific Advisor and Co-founder) of NTrans Technologies about CRISPR-Cas technology in “Analyse Nederland”: https://analysenederland.nl/article/john-van-der-oost-darwin-zou-crispr-cas-technologie-juist-fantastisch-vinden.html